Acadia Pharmaceuticals (ACAD) Current Assets (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Current Assets of $1.1 billion for Q1 2026, up 25.84% year-over-year from $870.9 million in Q1 2025, and up 3.19% quarter-over-quarter from $1.1 billion in Q4 2025.
Acadia Pharmaceuticals (ACAD) Current Assets (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Current Assets rose 25.84% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 25.84% YoY), while the FY2025 annual figure was $1.1 billion, up 13.19% from the prior year.
- Current Assets for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Current Assets was $1.1 billion in Q1 2026, with the low at $492.6 million in Q2 2023.
- The 5-year median for Current Assets is $675.3 million (2024), against an average of $730.1 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets retreated 19.55% in 2022, then soared 57.92% in 2024.
- Acadia Pharmaceuticals' Current Assets stood at $507.9 million in 2022, then increased by 21.3% to $616.1 million in 2023, then soared by 52.29% to $938.3 million in 2024, then gained by 13.19% to $1.1 billion in 2025, then advanced by 3.19% to $1.1 billion in 2026.
- Business Quant data shows ACAD's Current Assets at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 1.22 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Bn |
| Mar 31, 2026 | 1.10 Bn |
| Dec 31, 2025 | 1.06 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 960.55 Mn |
| Mar 31, 2025 | 870.94 Mn |
| Dec 31, 2024 | 938.32 Mn |
| Sep 30, 2024 | 788.28 Mn |
| Jun 30, 2024 | 728.92 Mn |
| Mar 31, 2024 | 675.30 Mn |
| Dec 31, 2023 | 616.13 Mn |
| Sep 30, 2023 | 499.17 Mn |
| Jun 30, 2023 | 492.63 Mn |
| Mar 31, 2023 | 502.85 Mn |
| Dec 31, 2022 | 507.94 Mn |
| Sep 30, 2022 | 521.55 Mn |
| Jun 30, 2022 | 532.52 Mn |
| Mar 31, 2022 | 542.22 Mn |
| Dec 31, 2021 | 617.82 Mn |
| Sep 30, 2021 | 640.92 Mn |